LP352 is named as a drug or biological intervention in 3 clinical trials in our UK, USA and China trial registers, none of which are currently recruiting. The lead sponsor is Longboard Pharmaceuticals. Registered phase: Phase 3. Conditions studied include Developmental and Epileptic Encephalopathy; Dravet Syndrome.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06908226 | A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE) Developmental and Epileptic Encephalopathy |
Phase 3 | By invitation |
| NCT06660394 | A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) (ClinicalTrials.gov ↗) Dravet Syndrome |
Phase 3 | Active, closed |
| NCT06719141 | A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE) (ClinicalTrials.gov ↗) Developmental and Epileptic Encephalopathy |
Phase 3 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Developmental and Epileptic Encephalopathy | 2 |
| Dravet Syndrome | 1 |
| Lead sponsor | Trials |
|---|---|
| Longboard Pharmaceuticals | 3 |
| Register | LP352 trials |
|---|---|
| Clinical trials in UK | 3 |
| Clinical trials in USA | 3 |
| Clinical trials in China | 3 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how LP352 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists LP352 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.